GlassScriptPhysician profile
Bilal Khan
NPI 1235795410
$3,860.81
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,004 · 2023: $369 · 2024: $333 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.81 |
| Education | $212.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supreme Orthopedic Systems, LLC | $1,200.00 | 2022 | |
| Stryker Corporation | $866.50 | 2022 | |
| Medical Device Business Services, INC. | $659.42 | 2022 | |
| Djo, LLC | $306.38 | 2023-2025 | Dr Comfort, Cmf |
| Arthrex, INC. | $278.08 | 2022 | |
| Organogenesis INC. | $236.70 | 2024-2025 | Nushield |
| Treace Medical Concepts, INC. | $66.35 | 2024-2025 | |
| Next Science LLC | $49.40 | 2023-2024 | Blastx, Surgx, Xperience |
| Bioventus LLC | $48.29 | 2023-2024 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Nevro Corp. | $44.69 | 2023 | Senza |
| Paratek Pharmaceuticals, INC. | $43.02 | 2024-2025 | Nuzyra |
| Kerecis Limited | $37.79 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $24.19 | 2023 | Renasys Go V2 Home, Pico |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.